Wernicke A Gabriella, Hirschfeld Cole B, Smith Andrew W, Taube Shoshana, Yondorf Menachem Z, Parashar Bhupesh, Nedialkova Lucy, Kulidzhanov Fridon, Trichter Samuel, Sabbas Albert, Ramakrishna Rohan, Pannullo Susan, Schwartz Theodore H
Stich Radiation Oncology, Weill Cornell Medical College/NewYork-Presbyterian Hospital, New York, New York; Department of Neurosurgery, Brain and Spine Center, Weill Cornell Medical College/NewYork-Presbyterian Hospital, New York, New York.
Weill Cornell Medical College, New York, New York.
Int J Radiat Oncol Biol Phys. 2017 Aug 1;98(5):1059-1068. doi: 10.1016/j.ijrobp.2017.03.044. Epub 2017 Jun 10.
Studies on adjuvant stereotactic radiosurgery to the cavity of resected brain metastases have suggested that larger tumors (>2.0 cm) have greater rates of recurrence and radionecrosis (RN). The present study assessed the effect of permanent low-dose Cs brachytherapy on local control and RN in patients treated for large brain metastases.
After institutional review board approval, 42 patients with 46 metastases ≥2.0 cm in preoperative diameter were accrued to a prospective trial from 2010 to 2015. Patients underwent surgical resection with intraoperative placement of stranded Cs seeds as permanent volume implants in the resection cavity. The primary endpoint was local freedom from progression (FFP). Secondary endpoints included regional and distant FFP, overall survival (OS), and RN rate. Failures 5 to 20 mm from the cavity and dural-based failures were considered regional. A separate analysis was performed for metastases >3.0 cm.
Of the 46 metastases, 18 were >3.0 cm in diameter. The median follow-up period was 11.9 months (range 0.6-51.9). The metastases had a median preoperative diameter of 3.0 cm (range 2.0-6.8). The local FFP rate was 100% for all tumor sizes. Regional recurrence developed in 3 of 46 lesions (7%), for a 1-year regional FFP rate of 89% (for tumors >3.0 cm, the FFP rate was 80%, 95% confidence interval 54%-100%). Distant recurrences were found in 19 of 46 lesions (41%), for a 1-year distant FFP rate of 52%. The median OS was 15.1 months, with a 1-year OS rate of 58%. Lesion size was not significantly associated with any endpoint on univariate or multivariate analysis. Radioresistant histologic features resulted in worse survival (P=.036). No cases of RN developed.
Intraoperative Cs brachytherapy is a promising and effective therapy for large brain metastases requiring neurosurgical intervention, which can offer improved local control and lower rates of RN compared with stereotactic radiosurgery to the resection cavity.
关于对切除后的脑转移瘤腔进行辅助立体定向放射外科治疗的研究表明,较大的肿瘤(>2.0 cm)复发率和放射性坏死(RN)发生率更高。本研究评估了永久性低剂量铯近距离放射治疗对接受大体积脑转移瘤治疗患者的局部控制和放射性坏死的影响。
经机构审查委员会批准,2010年至2015年期间,42例患者的46个术前直径≥2.0 cm的转移瘤被纳入一项前瞻性试验。患者接受手术切除,术中将 stranded Cs 种子作为永久性体积植入物放置在切除腔内。主要终点是局部无进展生存期(FFP)。次要终点包括区域和远处FFP、总生存期(OS)和RN发生率。距瘤腔5至20 mm处的复发和硬脑膜相关复发被视为区域复发。对直径>3.0 cm的转移瘤进行了单独分析。
46个转移瘤中,18个直径>3.0 cm。中位随访期为11.9个月(范围0.6 - 51.9个月)。转移瘤术前中位直径为3.0 cm(范围2.0 - 6.8 cm)。所有肿瘤大小的局部FFP率均为100%。46个病灶中有3个发生区域复发(7%),1年区域FFP率为89%(对于直径>3.0 cm的肿瘤,FFP率为80%,95%置信区间54% - 100%)。46个病灶中有19个发生远处复发(41%),1年远处FFP率为52%。中位OS为15.1个月,1年OS率为58%。在单因素或多因素分析中,病灶大小与任何终点均无显著相关性。放射抵抗性组织学特征导致生存期较差(P = 0.036)。未发生RN病例。
术中铯近距离放射治疗对于需要神经外科干预的大体积脑转移瘤是一种有前景且有效的治疗方法,与对切除腔进行立体定向放射外科治疗相比,它可以提供更好的局部控制并降低RN发生率。